

EXCEPTION REQUEST FORM
Opioid MED Request - Medicare

Unless otherwise indicated below, authorization quantities are limited to the manufacturer recommended dosage



P.O. Box 30192
Salt Lake City, UT 84130-0192

SELECTHEALTH.ORG

Complete online at www.selecthealth.org/pa or fax back to: 801-650-3170
For questions or clarifications, call: 801-442-9988 or 855-442-9988

Patient Information

Patient's Name:	Patient's Date of Birth:
Patient's ID:	Patient's Phone #:
Diagnosis Code(s):	

Requesting Provider Information

Name:	Phone #:
NPI/DEA:	Fax #:
Address:	Supervising Physician (if requesting provider bills under a different provider)
	Name:
	NPI/DEA:

Drug Name and Strength:	Directions / SIG:
<input type="checkbox"/> Urgent Request (24 hours)	<input type="checkbox"/> Standard Request (72 hours)

Q1. Which medication is being requested (please include medication name, strength, and dosage)?

Q2. Is the request for a brand name medication that has a commercially available generic equivalent?

Yes No

Q3. If yes, please indicate why the generic equivalent cannot be used:

Q4. Does the patient have a diagnosis of cancer or reside in a hospice or palliative care center?

Yes No

Q5. If no, please provide the member's diagnosis:

<p>Q6. Has the patient been stable on the dose requested?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q7. If yes, please provide the duration of therapy:</p>
<p>Q8. Is this a request to increase the patient's current opioid regimen?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q9. If yes, please indicate if this is a long-term or short-term increase (expected length of therapy) and provide medical rationale for the increase:</p>
<p>Q10. Have attempts been made to reduce the patients cumulative daily morphine equivalent opioid dose?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q11. Has the patient tried and failed therapy with non-steroidal anti-inflammatory drugs (e.g. ibuprofen, meloxicam, naproxen, diclofenac, etodolac, etc.)?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q12. If yes, please list the medication name(s), dosage, and duration of therapy:</p>
<p>Q13. Has the patient tried and failed therapy with long-acting opioid therapies (e.g. Oxycontin, MS Contin, oxymorphone ER, fentanyl patches, etc.)?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q14. If yes, please list the medication name(s), dosage, and duration of therapy:</p>
<p>Q15. Has the patient tried and failed therapy with short-acting opioid therapies (e.g. Percocet, Norco, Percodan, Roxicodone, etc.)?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q16. If yes, please list the medication name(s), dosage, and duration of therapy:</p>
<p>Q17. Has the patient tried and failed therapy with any other non-opioid interventions?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q18. If yes, please list the medication name(s), dosage, and duration of therapy:</p>
<p>Q19. Aside from being stable on the requested dose (when applicable), please provide additional rationale for the member to receive opioid therapy at or above 200 morphine equivalents daily: (Note, the Centers for Disease Control and Prevention (CDC) has recommended that cumulative daily doses of 90 morphine equivalents or more should be avoided and should be carefully justified.)</p>

Q20. Chart notes or a letter of medical necessity are required for the request of this medication. Failure to provide them will result in a delay in decision and/or denial. Did you attach relevant chart notes and a letter of medical necessity?

Yes

No

Q21. Additional Comments:

This form is intended for SelectHealth members only. All requests for preauthorization should be sent via fax to 1-801-442-0413. Missing, inaccurate, or incomplete information may cause a delay or denial of authorization.

Prescriber Signature

Date

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document.